{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Uterine+Corpus+Leiomyosarcoma",
    "query": {
      "condition": "Unresectable Uterine Corpus Leiomyosarcoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T03:12:19.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00004066",
      "title": "Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "1999-06",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004066"
    },
    {
      "nct_id": "NCT00033709",
      "title": "Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Herbert Irving Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033709"
    },
    {
      "nct_id": "NCT05432791",
      "title": "Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Uterine Corpus Leiomyosarcoma",
        "Metastatic Uterine Corpus Leiomyosarcoma",
        "Stage III Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8",
        "Unresectable Uterine Corpus Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Trabectedin",
          "type": "DRUG"
        },
        {
          "name": "Transthoracic Echocardiography Test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2023-03-30",
      "completion_date": "2027-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 144,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Dublin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432791"
    },
    {
      "nct_id": "NCT00390234",
      "title": "Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Female Reproductive Cancer",
        "Ovarian Carcinosarcoma",
        "Ovarian Sarcoma",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Uterine Sarcoma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Uterine Sarcoma",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Uterine Sarcoma",
        "Uterine Carcinosarcoma",
        "Uterine Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 63,
      "start_date": "2006-09",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00390234"
    },
    {
      "nct_id": "NCT02601209",
      "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Sarcoma",
        "Metastatic Leiomyosarcoma",
        "Metastatic Malignant Peripheral Nerve Sheath Tumor",
        "Metastatic Synovial Sarcoma",
        "Metastatic Undifferentiated Pleomorphic Sarcoma",
        "Metastatic Unresectable Sarcoma",
        "Myxofibrosarcoma",
        "Recurrent Leiomyosarcoma",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Synovial Sarcoma",
        "Recurrent Undifferentiated Pleomorphic Sarcoma",
        "Stage III Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Unresectable Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2015-11-30",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 460,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601209"
    },
    {
      "nct_id": "NCT01132547",
      "title": "Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "cyproheptadine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2010-06",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2015-07-02",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132547"
    },
    {
      "nct_id": "NCT04200443",
      "title": "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Leiomyosarcoma",
        "Metastatic Soft Tissue Sarcoma",
        "Stage III Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Unresectable Leiomyosarcoma",
        "Unresectable Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2020-01-14",
      "completion_date": "2026-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Chicago, Illinois • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200443"
    },
    {
      "nct_id": "NCT02428192",
      "title": "Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Leiomyosarcoma",
        "Unresectable Leiomyosarcoma",
        "Uterine Corpus Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2015-05-19",
      "completion_date": "2021-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-09-30T03:12:19.343Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02428192"
    }
  ]
}